Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PTC Therapeutics's interest expense for the
three
months ended in Mar. 2022 was $ -23.5 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was $-90.4 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PTC Therapeutics's Operating Income for the
three
months ended in Mar. 2022 was $ -98.2 Mil. PTC Therapeutics's Interest Expense for the
three
months ended in Mar. 2022 was $ -23.5 Mil.
PTC Therapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
PTC Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-90.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTC Therapeutics (NAS:PTCT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
PTC Therapeutics's Interest Expense for the
three
months ended in Mar. 2022 was $-23.5 Mil. Its
Operating Income
for the
three
months ended in Mar. 2022 was $-98.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2022 was $373.3 Mil.
PTC Therapeutics's Interest Coverage for the quarter that ended in Mar. 2022 is calculated as
| PTC Therapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
PTC Therapeutics Business Description
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
| Southwell David P |
director |
C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
| Jacobson Allan Steven |
director |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Peltz Stuart Walter |
director, officer: Chief Executive Officer |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Utter Christine Marie |
officer: SVP, Finance & CAO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Boulding Mark Elliott |
officer: Exec. VP and CLO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Hill Emily Luisa |
officer: Chief Financial Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Svoronos Dawn |
director |
C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
| Pauwels Eric |
officer: Chief Business Officer |
550 HILLS DRIVE BEDMINSTER NJ 07921 |
| Klein Matthew B. |
officer: Chief Development Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Schmertzler Michael |
director |
1300 VALLEY ROAD NEW CANAAN CT 06840 |
| Souza Marcio |
officer: Chief Operating Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Almstead Neil Gregory |
officer: Chief Technical Ops Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Reeve Emma |
director |
C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
| Steele Glenn Jr Md Phd |
director |
250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
| Zeldis Jerome B |
director |
8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
PTC Therapeutics Headlines
By Seekingalpha 2020-08-28
By Seekingalpha 2022-02-23
By Seekingalpha 2020-10-30
By Seekingalpha 2021-10-29
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.45(1.41%) Volume: 54,176 10:09AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
